



# 1. Bölüm

## İSKEMİ REPERFÜZYON HASARI VE MEKANİZMASI

Ayşegül KÜÇÜK<sup>1</sup>

Ümmü Gülsen BOZOK<sup>2</sup>

Mustafa ARSLAN<sup>3</sup>

### 1.1. İskemi Reperfüzyon

İskemi, bir dokunun normal işlevi için ihtiyacı olan kan ile beslenmesidir. İskemi süresinin artmasıyla, etkilenen dokularda yapısal bütünlük kaybı ile karakterize geri dönüşü olmayan yaralanmalar oluşmaya başlar ve hücre ölümü gerçekleşir. Doku hasarının olmaması için kan akımının hızla yeniden sağlanması gereklidir. Reperfüzyon olarak adlandırılan bu olay, hücre işlevleri için gerekli olan oksijen ve besin ihtiyacını yeniden sağlayarak iskemik bölgeden metabolitleri uzaklaştırır. Reperfüzyon aynı zamanda hasarlı hücrelerdeki yaranmayı şiddetlendirebilir ve yeni hücrelerin hasarlanmasına sebep olabilir. Bu durum, kalp, akciğer, böbrek, bağırsak, iskelet kası ve beyin dahil olmak üzere birçok organda meydana gelebilir ve bu süreçte oluşan metabolitler kan dolaşımı yoluyla uzak organlara gidebilir. Yani, sadece iskemik organın kendisini değil, aynı zamanda uzak organlarda sistemik hasara neden olarak çoklu organ yetmezliğine yol açabilir. Bir organa kan akımının kısıtlanması ile başlayan ve kan akımının yeniden sağlanması ile meydana gelen hücresel hasar ve/veya organ yetmezliği ve/veya ölümden oluşan olaylar bütününe iskemi reperfüzyon (I/R) hasarı denir (1).

<sup>1</sup> Prof. Dr., Kütahya Sağlık Bilimleri Üniversitesi Tıp Fakültesi, Fizyoloji AD., kucukaysegul@hotmail.com

<sup>2</sup> Öğr. Gör. Dr., Kütahya Sağlık Bilimleri Üniversitesi Tıp Fakültesi, Fizyoloji AD., gulsenozsoy07@gmail.com

<sup>3</sup> Doç. Dr., Gazi Üniversitesi Tıp Fakültesi, Anesteziyoloji ve Reanimasyon AD., mustarslan@gmail.com

## KAYNAKLAR

1. Cowled P, Fitridge R. Pathophysiology of reperfusion injury. In: Fitridge R, Thompson M, editors. *Mechanisms of vascular disease: A reference book for Vascular Specialists*. Adelaide (AU): University of Adelaide Press; 2011. 18. PMID: 30485021.
2. Ong SB, Samangouei P, Kalkhoran SB, Hausenloy DJ. The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. *J Mol Cell Cardiol* 2015;78:23-34.
3. Szydlowska K, Tymianski M. Calcium, ischemia and excitotoxicity. *Cell Calcium* 2010;47(2):122-9.
4. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Ischemia/reperfusion. *Compr Physiol* 2016;7(1):113-170.
5. Granger A, Abdullah I, Huebner F, Stout A, Wang T, Huebner T, et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. *FASEB J* 2008;22(10):3549-60.
6. Parks DA, Granger DN. Xanthine oxidase: biochemistry, distribution and physiology. *Acta Physiol Scand Suppl* 1986;548:87-99.
7. Goldman G, Welbourn R, Klausner JM, Kobzik L, Valeri CR, Shepro D, et al. Mast cells and leukotrienes mediate neutrophil sequestration and lung edema after remote ischemia in rodents. *Surgery* 1992;112(3):578-86.
8. Kvietys PR, Granger DN. Role of reactive oxygen and nitrogen species in the vascular responses to inflammation. *Free Radic Biol Med* 2012;52(3):556-92.
9. Jiang F, Zhang Y, Dusting GJ. NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. *Pharmacol Rev* 2011;63(1):218-42.
10. Dvorianchikova G, Degterev A, Ivanov D. Retinal ganglion cell (RGC) programmed necrosis contributes to ischemia-reperfusion-induced retinal damage. *Exp Eye Res* 2014;123:1-7.
11. Deng Y, Theken KN, Lee CR. Cytochrome P450 epoxigenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. *J Mol Cell Cardiol* 2010;48(2):331-41.
12. Ellett JD, Atkinson C, Evans ZP, Amani Z, Balish E, Schmidt MG, et al. Murine Kupffer cells are protective in total hepatic ischemia/reperfusion injury with bowel congestion through IL-10. *J Immunol* 2010;184(10):5849-58.
13. Roe ND, Ren J. Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases. *Vascul Pharmacol* 2012;57(5-6):168-72.
14. Settergren M, Böhm F, Malmström RE, Channon KM, Pernow J. L-arginine and tetrahydrobiopterin protects against ischemia/reperfusion-induced endothelial dysfunction in patients with type 2 diabetes mellitus and coronary artery disease. *Atherosclerosis* 2009;204(1):73-8.
15. Lee HL, Chen CL, Yeh ST, Zweier JL, Chen YR. Biphasic modulation of the mitochondrial electron transport chain in myocardial ischemia and reperfusion. *Am J Physiol Heart Circ Physiol* 2012;302(7):H1410-22.
16. Perrelli MG, Pagliaro P, Penna C. Ischemia/reperfusion injury and cardioprotective mechanisms: Role of mitochondria and reactive oxygen species. *World J Cardiol* 2011;3(6):186-200.
17. Chouchani ET, Pell VR, Gaude E, Aksentijević D, Sundier SY, Robb EL, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. *Nature* 2014;515(7527):431-5.
18. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. *Physiol Rev* 2014;94(3):909-50.
19. Carpi A, Menabò R, Kaludercic N, Pelicci P, Di Lisa F, Giorgio M. The cardioprotective effects elicited by p66(Shc) ablation demonstrate the crucial role of mitochondrial ROS formation in ischemia/reperfusion injury. *Biochim Biophys Acta* 2009;1787(7):774-80.
20. Inagaki T, Akiyama T, Du CK, Zhan DY, Yoshimoto M, Shirai M. Monoamine oxidase-induced hydroxyl radical production and cardiomyocyte injury during myocardial ischemia-reperfusion in rats. *Free Radic Res* 2016;50(6):645-53.

21. Arany I, Faisal A, Clark JS, Vera T, Baliga R, Nagamine Y. p66SHC-mediated mitochondrial dysfunction in renal proximal tubule cells during oxidative injury. *Am J Physiol Renal Physiol* 2010;298(5):F1214-21.
22. Yang M, Stowe DF, Udoh KB, Heisner JS, Camara AK. Reversible blockade of complex I or inhibition of PKC $\beta$  reduces activation and mitochondria translocation of p66Shc to preserve cardiac function after ischemia. *PLoS One* 2014;9(12):e113534. doi: 10.1371/journal.pone.0113534.
23. Bianchi P, Kunduzova O, Masini E, Cambon C, Bani D, Raimondi L, et al. Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury. *Circulation* 2005;112(21):3297-305.
24. Di Lisa F, Kaludercic N, Carpi A, Menabò R, Giorgio M. Mitochondria and vascular pathology. *Pharmacol Rep* 2009;61(1):123-30.
25. Johnston WH, Latta H. Glomerular mesangial and endothelial cell swelling following temporary renal ischemia and its role in the no-reflow phenomenon. *Am J Pathol* 1977;89(1):153-66.
26. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. *Cardiovasc Res* 2004;61(3):498-511.
27. Fernández-Klett F, Offenhauser N, Dirnagl U, Priller J, Lindauer U. Pericytes in capillaries are contractile in vivo, but arterioles mediate functional hyperemia in the mouse brain. *Proc Natl Acad Sci U S A* 2010;107(51):22290-5.
28. Yemisci M, Gursoy-Ozdemir Y, Vural A, Can A, Topalkara K, Dalkara T. Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. *Nat Med* 2009;15(9):1031-7.
29. Clerk A, Fuller SJ, Michael A, Sugden PH. Stimulation of "stress-regulated" mitogen-activated protein kinases (stress-activated protein kinases/c-Jun N-terminal kinases and p38-mitogen-activated protein kinases) in perfused rat hearts by oxidative and other stresses. *J Biol Chem* 1998;273(13):7228-34.
30. Kaiser RA, Liang Q, Bueno O, Huang Y, Lackey T, Klevitsky R, et al. Genetic inhibition or activation of JNK1/2 protects the myocardium from ischemia-reperfusion-induced cell death in vivo. *J Biol Chem* 2005;280(38):32602-8.
31. Lee KH, Kim SE, Lee YS. SP600125, a selective JNK inhibitor, aggravates hepatic ischemia-reperfusion injury. *Exp Mol Med* 2006;38(4):408-16.
32. Ma XL, Kumar S, Gao F, Louden CS, Lopez BL, Christopher TA, et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. *Circulation* 1999;99(13):1685-91.
33. Yusof M, Kamada K, Kalogeris T, Gaskin FS, Korthuis RJ. Hydrogen sulfide triggers late-phase preconditioning in postischemic small intestine by an NO- and p38 MAPK-dependent mechanism. *Am J Physiol Heart Circ Physiol* 2009;296(3):H868-76.
34. Das M, Cui J, Das DK. Generation of survival signal by differential interaction of p38MAP-Kalpha and p38MAPKbeta with caveolin-1 and caveolin-3 in the adapted heart. *J Mol Cell Cardiol* 2007;42(1):206-13.
35. Strasser RH, Simonis G, Schön SP, Braun MU, Ihl-Vahl R, Weinbrenner C, Marquetant R, Kübler W. Two distinct mechanisms mediate a differential regulation of protein kinase C isozymes in acute and prolonged myocardial ischemia. *Circ Res* 1999;85(1):77-87.
36. Churchill EN, Mochly-Rosen D. The roles of PKCdelta and epsilon isoenzymes in the regulation of myocardial ischaemia/reperfusion injury. *Biochem Soc Trans* 2007;35(Pt 5):1040-2.
37. Ai X, Curran JW, Shannon TR, Bers DM, Pogwizd SM. Ca $^{2+}$ /calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca $^{2+}$  leak in heart failure. *Circ Res* 2005;97(12):1314-22.
38. Ferraro FJ, Rush BF Jr, Simonian GT, Bruce CJ, Murphy TF, Hsieh JT, et al. A comparison of survival at different degrees of hemorrhagic shock in germ-free and germ-bearing rats. *Shock* 1995;4(2):117-20.

39. Miao W, Qu Z, Shi K, Zhang D, Zong Y, Zhang G, et al. RIP3 S-nitrosylation contributes to cerebral ischemic neuronal injury. *Brain Res* 2015;1627:165-76.
40. Levine AJ, Parkes K, Rooney SJ, Bonser RS. The effect of adhesion molecule blockade on pulmonary reperfusion injury. *Ann Thorac Surg* 2002;73(4):1101-6.
41. Huang J, Choudhri TF, Winfree CJ, McTaggart RA, Kiss S, Mocco J, et al. Postischemic cerebrovascular E-selectin expression mediates tissue injury in murine stroke. *Stroke* 2000;31(12):3047-53.
42. Yilmaz G, Granger DN. Cell adhesion molecules and ischemic stroke. *Neurol Res* 2008;30(8):783-93.
43. Sun Z, Wang X, Lasson A, Böjesson A, Annborn M, Andersson R. Effects of inhibition of PAF, ICAM-1 and PECAM-1 on gut barrier failure caused by intestinal ischemia and reperfusion. *Scand J Gastroenterol* 2001;36(1):55-65.
44. Boros P, Bromberg JS. New cellular and molecular immune pathways in ischemia/reperfusion injury. *Am J Transplant* 2006;6(4):652-8.
45. Birdsall HH, Green DM, Trial J, Youker KA, Burns AR, MacKay CR, et al. Complement C5a, TGF-beta 1, and MCP-1, in sequence, induce migration of monocytes into ischemic canine myocardium within the first one to five hours after reperfusion. *Circulation* 1997;95(3):684-92.
46. Charlagonra P, Liu J, Patel M, Rushbrook JI, Zhang M. Loss of plasma membrane integrity, complement response and formation of reactive oxygen species during early myocardial ischemia/reperfusion. *Mol Immunol* 2013;56(4):507-12.
47. Goretti E, Wagner DR, Devaux Y. miRNAs as biomarkers of myocardial infarction: a step forward towards personalized medicine? *Trends Mol Med* 2014;20(12):716-25.
48. Kumar P, Shen Q, Pivetti CD, Lee ES, Wu MH, Yuan SY. Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. *Expert Rev Mol Med* 2009;11:e19. doi: 10.1017/S1462399409001112.
49. Rodrigues SF, Granger DN. Role of blood cells in ischaemia-reperfusion induced endothelial barrier failure. *Cardiovasc Res* 2010;87(2):291-9.
50. Gould TJ, Vu TT, Swystun LL, Dwivedi DJ, Mai SH, Weitz JI, et al. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. *Arterioscler Thromb Vasc Biol* 2014;34(9):1977-84.
51. Zhang C, Wu J, Xu X, Potter BJ, Gao X. Direct relationship between levels of TNF-alpha expression and endothelial dysfunction in reperfusion injury. *Basic Res Cardiol* 2010;105(4):453-64.
52. Hein TW, Zhang C, Wang W, Chang CI, Thengchaisri N, Kuo L. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. *FASEB J* 2003;17(15):2328-30.
53. Tiefenbacher CP, Chilian WM, Mitchell M, DeFily DV. Restoration of endothelium-dependent vasodilation after reperfusion injury by tetrahydrobiopterin. *Circulation* 1996 Sep;94(6):1423-9.
54. Barrabés JA, Inserte J, Mirabet M, Quiroga A, Hernando V, Figueras J, et al. Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts. *Thromb Haemost* 2010;104(1):128-35.
55. Caldwell CC, Okaya T, Martignoni A, Husted T, Schuster R, Lentsch AB. Divergent functions of CD4+ T lymphocytes in acute liver inflammation and injury after ischemia-reperfusion. *Am J Physiol Gastrointest Liver Physiol* 2005;289(5):G969-76.
56. Atarashi K, Hirata T, Matsumoto M, Kanemitsu N, Miyasaka M. Rolling of Th1 cells via P-selectin glycoprotein ligand-1 stimulates LFA-1-mediated cell binding to ICAM-1. *J Immunol* 2005;174(3):1424-32.
57. Shen XD, Ke B, Zhai Y, Gao F, Anselmo D, Lassman CR, et al. Stat4 and Stat6 signaling in hepatic ischemia/reperfusion injury in mice: HO-1 dependence of Stat4 disruption-mediated cytoprotection. *Hepatology* 2003;37(2):296-303.

58. Syrjälä SO, Keränen MA, Tuuminen R, Nykänen AI, Tammi M, Krebs R, et al. Increased Th17 rather than Th1 alloimmune response is associated with cardiac allograft vasculopathy after hypothermic preservation in the rat. *J Heart Lung Transplant* 2010;29(9):1047-57.
59. Yang Z, Sharma AK, Linden J, Kron IL, Laubach VE. CD4+ T lymphocytes mediate acute pulmonary ischemia-reperfusion injury. *J Thorac Cardiovasc Surg* 2009;137(3):695-702; discussion 702.
60. Hanidzic D, Koulmanda M. Inflammation and the balance of Treg and Th17 cells in transplant rejection and tolerance. *Curr Opin Organ Transplant* 2010;15(4):411-5.
61. Park P, Haas M, Cunningham PN, Bao L, Alexander JJ, Quigg RJ. Injury in renal ischemia-reperfusion is independent from immunoglobulins and T lymphocytes. *Am J Physiol Renal Physiol* 2002;282(2):F352-7.
62. Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. *J Exp Med* 2006;203(12):2639-48.
63. Burne-Taney MJ, Ascon DB, Daniels F, Racusen L, Baldwin W, Rabb H. B cell deficiency confers protection from renal ischemia reperfusion injury. *J Immunol* 2003;171(6):3210-5.
64. Jang HR, Rabb H. Immune cells in experimental acute kidney injury. *Nat Rev Nephrol* 2015;11(2):88-101.
65. Huang Y, Rabb H, Womer KL. Ischemia-reperfusion and immediate T cell responses. *Cell Immunol* 2007;248(1):4-11.
66. Podestà MA, Cucchiari D, Ponticelli C. The diverging roles of dendritic cells in kidney allotransplantation. *Transplant Rev (Orlando)* 2015;29(3):114-20.
67. Felger JC, Abe T, Kaunzner UW, Gottfried-Blackmore A, Gal-Toth J, McEwen BS, et al. Brain dendritic cells in ischemic stroke: time course, activation state, and origin. *Brain Behav Immun* 2010;24(5):724-37.
68. Lam FW, Vijayan KV, Rumbaut RE. Platelets and Their Interactions with Other Immune Cells. *Compr Physiol* 2015;5(3):1265-80.
69. Andrews RK, Berndt MC. Platelet physiology and thrombosis. *Thromb Res* 2004;114(5-6):447-53.
70. Cooper D, Russell J, Chitman KD, Williams MC, Wolf RE, Granger DN. Leukocyte dependence of platelet adhesion in postcapillary venules. *Am J Physiol Heart Circ Physiol* 2004;286(5):H1895-900.
71. Dai H, Korthuis RJ. Mast Cell Proteases and Inflammation. *Drug Discov Today Dis Models* 2011;8(1):47-55.
72. Jin Y, Silverman AJ, Vannucci SJ. Mast cells are early responders after hypoxia-ischemia in immature rat brain. *Stroke* 2009;40(9):3107-12.
73. Yusof M, Kamada K, Gaskin FS, Korthuis RJ. Angiotensin II mediates postischemic leukocyte-endothelial interactions: role of calcitonin gene-related peptide. *Am J Physiol Heart Circ Physiol* 2007;292(6):H3032-7.
74. Lazarus B, Messina A, Barker JE, Hurley JV, Romeo R, Morrison WA, et al. The role of mast cells in ischaemia-reperfusion injury in murine skeletal muscle. *J Pathol* 2000;191(4):443-8.
75. Liao L, Harris NR, Granger DN. Oxidized low-density lipoproteins and microvascular responses to ischemia-reperfusion. *Am J Physiol* 1996;271(6 Pt 2):H2508-14.
76. Strbian D, Kovanen PT, Karjalainen-Lindsberg ML, Tatlisumak T, Lindsberg PJ. An emerging role of mast cells in cerebral ischemia and hemorrhage. *Ann Med* 2009;41(6):438-50.
77. Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. *Liver Int* 2006;26(10):1175-86.
78. Tsung A, Hoffman RA, Izuishi K, Critchlow ND, Nakao A, Chan MH, et al. Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. *J Immunol* 2005;175(11):7661-8.
79. Quesnelle KM, Bystrom PV, Toledo-Pereyra LH. Molecular responses to ischemia and reperfusion in the liver. *Arch Toxicol* 2015;89(5):651-7.

80. Jaeschke H, Farhood A, Bautista AP, Spolarics Z, Spitzer JJ. Complement activates Kupffer cells and neutrophils during reperfusion after hepatic ischemia. *Am J Physiol* 1993;264(4 Pt 1):G801-9.
81. Jaeschke H, Bautista AP, Spolarics Z, Spitzer JJ. Superoxide generation by neutrophils and Kupffer cells during in vivo reperfusion after hepatic ischemia in rats. *J Leukoc Biol* 1992;52(4):377-82.
82. Fayaz SM, Suvanish Kumar VS, Rajanikant GK. Necroptosis: who knew there were so many interesting ways to die? *CNS Neurol Disord Drug Targets* 2014;13(1):42-51.
83. Bauer I, Wanner GA, Rensing H, Alte C, Miescher EA, Wolf B, et al. Expression pattern of heme oxygenase isoenzymes 1 and 2 in normal and stress-exposed rat liver. *Hepatology* 1998;27(3):829-38.
84. Ge L, Zhou X, Ji WJ, Lu RY, Zhang Y, Zhang YD, et al. Neutrophil extracellular traps in ischemia-reperfusion injury-induced myocardial no-reflow: therapeutic potential of DNase-based reperfusion strategy. *Am J Physiol Heart Circ Physiol* 2015;308(5):H500-9.
85. Liao P, Wang SQ, Wang S, Zheng M, Zheng M, Zhang SJ, et al. p38 Mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. *Circ Res* 2002;90(2):190-6.
86. Dutta P, Nahrendorf M. Monocytes in myocardial infarction. *Arterioscler Thromb Vasc Biol* 2015;35(5):1066-70.
87. Ma Y, Wang J, Wang Y, Yang GY. The biphasic function of microglia in ischemic stroke. *Prog Neurobiol* 2017;157:247-272.
88. Angelillo-Scherrer A. Leukocyte-derived microparticles in vascular homeostasis. *Circ Res* 2012;110(2):356-69.
89. Chironi GN, Boulanger CM, Simon A, Dignat-George F, Freyssinet JM, Tedgui A. Endothelial microparticles in diseases. *Cell Tissue Res* 2009;335(1):143-51.
90. Tersteeg C, Heijnen HF, Eckly A, Pasterkamp G, Urbanus RT, Maas C, et al. FFlow-induced PROtrusions (FLIPRs): a platelet-derived platform for the retrieval of microparticles by monocytes and neutrophils. *Circ Res* 2014;114(5):780-91.
91. Baumgartner WA, Williams GM, Fraser CD Jr, Cameron DE, Gardner TJ, Burdick JF, et al. Cardiopulmonary bypass with profound hypothermia. An optimal preservation method for multiorgan procurement. *Transplantation* 1989;47(1):123-7.
92. Barnabei MS, Palpant NJ, Metzger JM. Influence of genetic background on ex vivo and in vivo cardiac function in several commonly used inbred mouse strains. *Physiol Genomics* 2010;42A(2):103-13.
93. Ordy JM, Wengenack TM, Bialobok P, Coleman PD, Rodier P, Baggs RB, et al. Selective vulnerability and early progression of hippocampal CA1 pyramidal cell degeneration and GFAP-positive astrocyte reactivity in the rat four-vessel occlusion model of transient global ischemia. *Exp Neurol* 1993;119(1):128-39.
94. Bluhmki E, Chamorro A, Dávalos A, Machnig T, Sauce C, Wahlgren N, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. *Lancet Neurol* 2009;8(12):1095-102.
95. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. *Lancet* 1996;348(9030):771-5.
96. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. *Lancet* 1993;342(8874):759-66.
97. McDougal WS. Renal perfusion/reperfusion injuries. *J Urol* 1988;140(6):1325-30.
98. Cerqueira NF, Hussni CA, Yoshida WB. Pathophysiology of mesenteric ischemia/reperfusion: a review. *Acta Cir Bras* 2005;20(4):336-43.
99. Kinross J, Warren O, Basson S, Holmes E, Silk D, Darzi A, et al. Intestinal ischemia/reperfusion injury: defining the role of the gut microbiome. *Biomark Med* 2009;3(2):175-92.

100. Wagers AJ, Conboy IM. Cellular and molecular signatures of muscle regeneration: current concepts and controversies in adult myogenesis. *Cell* 2005;122(5):659-67.
101. Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. *J Pathol* 2000;190(3):255-66.
102. Stallion A, Kou TD, Latifi SQ, Miller KA, Dahms BB, Dudgeon DL, et al. Ischemia/reperfusion: a clinically relevant model of intestinal injury yielding systemic inflammation. *J Pediatr Surg* 2005;40(3):470-7.
103. Sorkine P, Szold O, Halpern P, Gutman M, Greenglass M, Rudick V, et al. Gut decontamination reduces bowel ischemia-induced lung injury in rats. *Chest* 1997;112(2):491-5.
104. Colletti LM, Cortis A, Lukacs N, Kunkel SL, Green M, Strieter RM. Tumor necrosis factor up-regulates intercellular adhesion molecule 1, which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat. *Shock* 1998;10(3):182-91.
105. Souza DG, Mendonça VA, de A Castro MS, Poole S, Teixeira MM. Role of tachykinin NK receptors on the local and remote injuries following ischaemia and reperfusion of the superior mesenteric artery in the rat. *Br J Pharmacol* 2002;135(2):303-12.
106. Maekawa A, Lee JK, Nagaya T, Kamiya K, Yasui K, Horiba M, et al. Overexpression of calpastatin by gene transfer prevents troponin I degradation and ameliorates contractile dysfunction in rat hearts subjected to ischemia/reperfusion. *J Mol Cell Cardiol* 2003;35(10):1277-84.
107. Cao T, Pintér E, Al-Rashed S, Gerard N, Hoult JR, Brain SD. Neurokinin-1 receptor agonists are involved in mediating neutrophil accumulation in the inflamed, but not normal, cutaneous microvasculature: an in vivo study using neurokinin-1 receptor knockout mice. *J Immunol* 2000 May;164(10):5424-9.
108. Szabó A, Varga R, Keresztes M, Vízler C, Németh I, Rázga Z, et al. Ischemic limb preconditioning downregulates systemic inflammatory activation. *J Orthop Res* 2009;27(7):897-902.
109. Bøtker HE, Kharbanda R, Schmidt MR, Böttcher M, Kaltoft AK, Terkelsen CJ, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. *Lancet* 2010;375(9716):727-34.
110. Gyurkovics E, Aranyi P, Stangl R, Onody P, Ferreira G, Lotz G, et al. Postconditioning of the lower limb--protection against the reperfusion syndrome. *J Surg Res* 2011;169(1):139-47.
111. Sínay L, Kürthy M, Horváth S, Arató E, Shafiei M, Lantos J, et al. Ischaemic postconditioning reduces peroxide formation, cytokine expression and leukocyte activation in reperfusion injury after abdominal aortic surgery in rat model. *Clin Hemorheol Microcirc* 2008;40(2):133-42.
112. Ergün Y, Darendeli S, Imrek S, Kılıç M, Oksüz H. The comparison of the effects of anesthetic doses of ketamine, propofol, and etomidate on ischemia-reperfusion injury in skeletal muscle. *Fundam Clin Pharmacol* 2010;24(2):215-22.
113. Lee JM, Suh JK, Jeong JS, Cho SY, Kim DW. Antioxidant effect of lidocaine and procaine on reactive oxygen species-induced endothelial dysfunction in the rabbit abdominal aorta. *Korean J Anesthesiol* 2010;59(2):104-10.
114. Cuzzocrea S, Reiter RJ. Pharmacological action of melatonin in shock, inflammation and ischemia/reperfusion injury. *Eur J Pharmacol* 2001;426(1-2):1-10.
115. Laws PE, Spark JI, Cowled PA, Fitridge RA. The role of statins in vascular disease. *Eur J Vasc Endovasc Surg* 2004;27(1):6-16.
116. Cowled PA, Khanna A, Laws PE, Field JB, Varelias A, Fitridge RA. Statins inhibit neutrophil infiltration in skeletal muscle reperfusion injury. *J Surg Res* 2007;141(2):267-76.
117. Cowled PA, Khanna A, Laws PE, Field JB, Fitridge RA. Simvastatin plus nitric oxide synthase inhibition modulates remote organ damage following skeletal muscle ischemia-reperfusion injury. *J Invest Surg* 2008;21(3):119-26.

118. Okatani Y, Wakatsuki A, Enzan H, Miyahara Y. Edaravone protects against ischemia/reperfusion-induced oxidative damage to mitochondria in rat liver. *Eur J Pharmacol* 2003;465(1-2):163-70.
119. Abu-Amara M, Gurusamy KS, Hori S, Glantzounis G, Fuller B, Davidson BR. Pharmacological interventions versus no pharmacological intervention for ischaemia reperfusion injury in liver resection surgery performed under vascular control. *Cochrane Database Syst Rev* 2009;(4):CD007472. doi: 10.1002/14651858.CD007472.pub2.